Syntara Limited (ASX:SNT)

Market Cap	54.74M -53.8%
Revenue (ttm)	7.50M -8.0%
Net Income	-11.06M
EPS	-0.01
Shares Out	1.63B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	973,473
Average Volume	598,873
Open	0.0330
Previous Close	0.0340
Day's Range	0.0330 - 0.0335
52-Week Range	0.0230 - 0.0830
Beta	0.21
RSI	58.32
Earnings Date	May 1, 2026

About Syntara

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and is in Phase 1c/2 studies for patients with myelodysplastic syndrome. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a P...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 21
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SNT

Financial Performance

In fiscal year 2025, Syntara's revenue was 7.30 million, an increase of 26.61% compared to the previous year's 5.76 million. Losses were -7.92 million, -47.70% less than in 2024.